João C. Campos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
João C. Campos has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Cardoso Costa
UCIBIO—Applied Molecular Biosciences Unit, MedTech-Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
4 shared publications - Domingos Ferreira
UCIBIO, REQUIMTE, MEDTECH, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge de Viterbo Ferreira, 228, 4050-313 Porto, Portugal
3 shared publications - Salette Reis
Laboratório Associado Para a Química Verde (LAQV), REQUIMTE (Rede de Química e Tecnologia), Faculty of Pharmacy, University of Porto 4050-313 Porto, Portugal
3 shared publications - Ana Alves
UCIBIO—Applied Molecular Biosciences Unit, MedTech-Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Rua Jorge de Viterbo Ferreira 228, 4050-313 Porto, Portugal
1 shared publication - Cláudia Nunes
LAQV, REQUIMTE, Faculdade de Farmácia, Universidade do Porto, R. Jorge de Viterbo Ferreira 228, 4500-313 Porto, Portugal
1 shared publication Davide Cunha
UCIBIO, REQUIMTE, MedTech - Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal
1 shared publication
Latest Publications
- 1 January 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 118, 111413
Oromucosal precursors of in loco hydrogels for wound-dressing and drug delivery in oral mucositis: Retain, resist, and release
- 1 January 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 118, 111413
Oromucosal precursors of in loco hydrogels for wound-dressing and drug delivery in oral mucositis: Retain, resist, and release
- 1 July 2019
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 566, 126-140
Swellable polymeric particles for the local delivery of budesonide in oral mucositis
- 1 July 2019
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 566, 126-140
Swellable polymeric particles for the local delivery of budesonide in oral mucositis
- Open Access
Discovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations
Following our previous work on the antitumor activity of acetylated flavonosides, a new acetylated xanthonoside, 3,6-bis(2,3,4,6-tetra-O-acetyl-β-glucopyranosyl)xanthone (2), was synthesized and discovered as a potent inhibitor of tumor cell growth. The synthesis involved the glycosylation of 3,6-di-hydroxyxanthone (1) with acetobromo-α-d-glucose. Glycosylation with silver carbonate decreased the amount of glucose donor needed, comparative to the biphasic glycosylation. Xanthone 2 showed a potent anti-growth activity, with GI50 < 1 μM, in human cell lines of breast, lung, and glioblastoma cancers. Current treatment for invasive brain glioma is still inadequate and new agents against glioblastoma with high brain permeability are urgently needed. To overcome these issues, xanthone 2 was encapsulated in a liposome. To increase the well-known low stability of these drug carriers, a proliposome formulation was developed using the spray drying method. Both formulations were characterized and compared regarding three months stability and in vitro anti-growth activity. While the proliposome formulation showed significantly higher stability, it was at the expense of losing its biocompatibility as a drug carrier in higher concentrations. More importantly, the new xanthone 2 was still able to inhibit the growth of glioblastoma cells after liposome formulation.
Open AccessDiscovery of a New Xanthone against Glioma: Synthesis and Development of (Pro)liposome Formulations
Following our previous work on the antitumor activity of acetylated flavonosides, a new acetylated xanthonoside, 3,6-bis(2,3,4,6-tetra-O-acetyl-β-glucopyranosyl)xanthone (2), was synthesized and discovered as a potent inhibitor of tumor cell growth. The synthesis involved the glycosylation of 3,6-di-hydroxyxanthone (1) with acetobromo-α-d-glucose. Glycosylation with silver carbonate decreased the amount of glucose donor needed, comparative to the biphasic glycosylation. Xanthone 2 showed a potent anti-growth activity, with GI50 < 1 μM, in human cell lines of breast, lung, and glioblastoma cancers. Current treatment for invasive brain glioma is still inadequate and new agents against glioblastoma with high brain permeability are urgently needed. To overcome these issues, xanthone 2 was encapsulated in a liposome. To increase the well-known low stability of these drug carriers, a proliposome formulation was developed using the spray drying method. Both formulations were characterized and compared regarding three months stability and in vitro anti-growth activity. While the proliposome formulation showed significantly higher stability, it was at the expense of losing its biocompatibility as a drug carrier in higher concentrations. More importantly, the new xanthone 2 was still able to inhibit the growth of glioblastoma cells after liposome formulation.
- 1 July 2018
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 128, 131-146
Challenges in the local delivery of peptides and proteins for oral mucositis management
- 1 July 2018
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 128, 131-146
Challenges in the local delivery of peptides and proteins for oral mucositis management